FI106385B - Menetelmiä proteiini C:n tuottamiseksi - Google Patents

Menetelmiä proteiini C:n tuottamiseksi Download PDF

Info

Publication number
FI106385B
FI106385B FI945877A FI945877A FI106385B FI 106385 B FI106385 B FI 106385B FI 945877 A FI945877 A FI 945877A FI 945877 A FI945877 A FI 945877A FI 106385 B FI106385 B FI 106385B
Authority
FI
Finland
Prior art keywords
protein
cell line
human
adenovirus
cells
Prior art date
Application number
FI945877A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI945877A (fi
FI945877A0 (fi
Inventor
Brian William Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI945877A0 publication Critical patent/FI945877A0/fi
Publication of FI945877A publication Critical patent/FI945877A/fi
Application granted granted Critical
Publication of FI106385B publication Critical patent/FI106385B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI945877A 1993-12-15 1994-12-14 Menetelmiä proteiini C:n tuottamiseksi FI106385B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/168,035 US5618714A (en) 1993-12-15 1993-12-15 Methods for producing protein C
US16803593 1993-12-15

Publications (3)

Publication Number Publication Date
FI945877A0 FI945877A0 (fi) 1994-12-14
FI945877A FI945877A (fi) 1995-06-16
FI106385B true FI106385B (fi) 2001-01-31

Family

ID=22609820

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945877A FI106385B (fi) 1993-12-15 1994-12-14 Menetelmiä proteiini C:n tuottamiseksi

Country Status (28)

Country Link
US (1) US5618714A (uk)
EP (1) EP0658626B1 (uk)
JP (1) JP3662614B2 (uk)
KR (1) KR950018454A (uk)
CN (1) CN1107887A (uk)
AT (1) ATE196165T1 (uk)
AU (1) AU687914B2 (uk)
BR (1) BR9404991A (uk)
CA (1) CA2138101A1 (uk)
CO (1) CO4340654A1 (uk)
CZ (2) CZ315794A3 (uk)
DE (1) DE69425809T2 (uk)
DK (1) DK0658626T3 (uk)
ES (1) ES2149244T3 (uk)
FI (1) FI106385B (uk)
GR (1) GR3034909T3 (uk)
HU (1) HU219508B (uk)
IL (1) IL111983A0 (uk)
NO (1) NO944846L (uk)
NZ (1) NZ270140A (uk)
PE (1) PE42695A1 (uk)
PL (1) PL176381B1 (uk)
PT (1) PT658626E (uk)
RU (1) RU2110574C1 (uk)
SI (1) SI0658626T1 (uk)
UA (1) UA26870C2 (uk)
YU (1) YU73494A (uk)
ZA (1) ZA949981B (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19724543A1 (de) * 1997-06-11 1998-12-17 Philips Patentverwaltung Wechsler-Gerät für Informationsplatten
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
WO2003085138A1 (en) 2002-03-29 2003-10-16 Merck & Co., Inc. Methods of virus production
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
EP0245949B1 (en) * 1986-04-09 1997-10-29 Eli Lilly And Company A method of using eukaryotic expression vectors comprising the bk virus enhancer
EP0289586A4 (en) * 1986-11-17 1990-04-10 New England Medical Ct INCREASING GAMMA CARBOXYLATION OF RECOMBINANT, VITAMIN K-DEPENDENT PROTEINS.
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインc及びその製造方法
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
CA1332049C (en) * 1988-10-07 1994-09-20 Eli Lilly And Company Eukaryotic expression
ES2047946T3 (es) * 1989-08-11 1994-03-01 Zymogenetics Inc Metodos de cultivos celulares para producir proteina c activada.
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
JPH05276952A (ja) * 1991-01-29 1993-10-26 Teijin Ltd ヒトプロテインc発現ベクター

Also Published As

Publication number Publication date
IL111983A0 (en) 1995-03-15
DE69425809T2 (de) 2001-02-01
CZ290724B6 (cs) 2002-10-16
FI945877A (fi) 1995-06-16
ES2149244T3 (es) 2000-11-01
RU94043769A (ru) 1997-03-27
JPH07222589A (ja) 1995-08-22
EP0658626B1 (en) 2000-09-06
PE42695A1 (es) 1995-12-12
KR950018454A (ko) 1995-07-22
CA2138101A1 (en) 1995-06-16
ATE196165T1 (de) 2000-09-15
CZ315794A3 (en) 1995-10-18
EP0658626A1 (en) 1995-06-21
HU9403600D0 (en) 1995-02-28
DK0658626T3 (da) 2000-10-16
HU219508B (hu) 2001-04-28
ZA949981B (en) 1996-06-14
CO4340654A1 (es) 1996-07-30
CN1107887A (zh) 1995-09-06
UA26870C2 (uk) 1999-12-29
SI0658626T1 (en) 2001-02-28
NZ270140A (en) 1996-05-28
PT658626E (pt) 2001-01-31
AU8045294A (en) 1995-06-22
NO944846D0 (no) 1994-12-14
HUT69979A (en) 1995-09-28
FI945877A0 (fi) 1994-12-14
RU2110574C1 (ru) 1998-05-10
NO944846L (no) 1995-06-16
PL176381B1 (pl) 1999-05-31
AU687914B2 (en) 1998-03-05
GR3034909T3 (en) 2001-02-28
BR9404991A (pt) 1995-08-08
YU73494A (sh) 1997-03-07
US5618714A (en) 1997-04-08
JP3662614B2 (ja) 2005-06-22
PL306291A1 (en) 1995-06-26
DE69425809D1 (de) 2000-10-12

Similar Documents

Publication Publication Date Title
KR920010871B1 (ko) 동물세포의 배양
US5976833A (en) Method for animal cell culture
US5510261A (en) Method of controlling the degradation of glycoprotein oligosaccharides produced by cultured Chinese hamster ovary cells
AU2008345231B2 (en) Cell culture processes
Avgerinos et al. Spin filter perfusion system for high density cell culture: production of recombinant urinary type plasminogen activator in CHO cells
FI106385B (fi) Menetelmiä proteiini C:n tuottamiseksi
Chen et al. Temperature shift as a process optimization step for the production of pro-urokinase by a recombinant Chinese hamster ovary cell line in high-density perfusion culture
EP2451963B1 (en) Method of increasing the expression yield of vitamin k-dependent proteins
Tharmalingam et al. High yields of monomeric recombinant β‐interferon from macroporous microcarrier cultures under hypothermic conditions
Roychoudhury et al. Synthesis, regulation and production of urokinase using mammalian cell culture: a comprehensive review
US9175281B2 (en) Process for the purification of tissue plasminogen activator
EP0756003B1 (en) Method of culturing animal cells
CN100392079C (zh) 蛋白c或活化的蛋白c-样分子
AU2014274601B2 (en) Cell Culture Processes
Gudzenko et al. Thermal stability of Cryptococcus albidus α-L-rhamnosidase
US10301611B2 (en) Process for refolding recombinant chymotrypsin
Pak Expression of autocrine growth factors in Chinese Hamster ovary (CHO) cells.
WO2016198499A1 (en) IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
JPS6336782A (ja) ヒト組織プラスミノゲン活性化因子の産生法